01—Abstract
Summary
Summary of the 8-K filed April 29, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported first quarter 2026 results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K.
Net sales were $886.9 milliona, up 9% on a reported basis and 5% organically, versus $814.3 million in the prior year period. Orders were a record $988.3 million, up 13% reported and 10% organically. GAAP diluted EPS was $1.61 (up from $1.26), and adjusted diluted EPS was $2.00 (up from $1.75, or 14%).
Gross margin declined to 44.9%b from 45.3%, citing unfavorable mix and pressured price/cost, partly offset by productivity and volume leverage. Health & Science Technologies drove growth, with segment organic sales up 11%, attributed to AI-driven demand for data center power and semiconductor markets as well as strength in space and defense, partially offset by lower life sciences volumes. Cash generation was softer.
Operating cash flow was $103.7 millionc versus $105.7 million, and free cash flow was $86.0 million versus $91.4 million, reflecting the timing of customer payments and higher capital expenditures. The company returned $76 million through share repurchases and $53 million through dividends during the quarter. Total borrowings rose, with $100.0 million drawn under revolving credit facilities during the period, and long-term borrowings-net increased to $1,871.8 million from $1,820.1 million at year-end 2025.
Management raised its full-year 2026 guidance, now projecting organic sales growth of 3% to 4% (up from 1% to 2%) and adjusted diluted EPS of $8.35 to $8.55d (up from $8.15 to $8.35). Second quarter 2026 guidance calls for organic sales growth of 3% to 4% and adjusted diluted EPS of $2.07 to $2.12.
02—Key points
Key Highlights
- Net sales of $886.9 million rose 9% reported and 5% organically; orders reached a record $988.3 million, up 13% reported and 10% organically.
- GAAP diluted EPS of $1.61 rose from $1.26; adjusted diluted EPS of $2.00 rose 14% from $1.75.
- Health & Science Technologies net sales grew 17% (11% organic), driven by AI-related data center power and semiconductor demand plus space and defense strength.
- Gross margin declined 40 bps to 44.9%, reflecting unfavorable mix and pressured price/cost, partly offset by productivity and volume leverage.
- Free cash flow was $86.0 million versus $91.4 million a year earlier, with operating cash flow of $103.7 million, affected by customer payment timing and higher capex.
- Returned $76 million via share repurchases and $53 million via dividends in the quarter.
- Raised full-year 2026 guidance: organic sales growth of 3% to 4% (from 1% to 2%) and adjusted diluted EPS of $8.35 to $8.55 (from $8.15 to $8.35).
03—Questions
Frequently Asked Questions
Why did IDEX raise its full-year 2026 guidance?
The company said first quarter results were ahead of its expectations, led by continued momentum in its Health & Science Technologies growth platforms. Management stated that the strategy is translating into higher-quality growth and raised full-year organic sales growth guidance to 3% to 4% and adjusted diluted EPS guidance to $8.35 to $8.55.
What drove the strong orders and sales growth in the quarter?
Orders of $988.3 million were a record and rose 10% organically. Health & Science Technologies organic sales rose 11% on higher volumes tied to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense, partially offset by lower life sciences volumes. Price was positive across the businesses.
Why did gross margin and cash flow decline year over year?
Gross margin fell to 44.9% from 45.3% due to unfavorable mix and pressured price/cost, partly offset by net productivity improvements and volume leverage. Operating cash flow was slightly lower at $103.7 million, reflecting the timing of customer payments, and free cash flow fell to $86.0 million from $91.4 million because of higher capital expenditures.
What did IDEX do with its capital in the quarter?
IDEX repurchased $76 million of common stock and paid $53 million in dividends. It also borrowed $100.0 million under revolving credit facilities, and long-term borrowings-net increased to $1,871.8 million from $1,820.1 million at December 31, 2025.
What is the company's outlook for the second quarter of 2026?
IDEX projects second quarter 2026 organic sales to increase 3% to 4% over the prior year period and adjusted diluted EPS of $2.07 to $2.12.
04—Continue